FDA Clearance Tracker · P150019
PARADIGM REAL-TIME REVEL SYSTEM
Last checked: Nov 19, 2026Latest source record: Dec 7, 2015 (this decision)Source: openFDAMethods & limitations
Decided
Dec 7, 2015
Approved
Time to decision
180 days
Received Jun 10, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P150019
- Device name
- PARADIGM REAL-TIME REVEL SYSTEM
- Applicant
- Medtronic Minimed
- Applicant location
- Northridge, CA
- Received
- Jun 10, 2015
- Decided
- Dec 7, 2015
- Decision
- Approved
- Supplements
- 61 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE PARADIGM REAL-TIME REVEL SYSTEM. THIS DEVICE IS INDICATED FOR:PARADIGM REAL-TIME REVEL INSULIN PUMP. THE PARADIGM REAL-TIME REVEL INSULIN PUMPS (MMT-523/MMT-723) ARE INDICATED FOR THE CONTINUOUS DELIVERY OF INSULIN, AT SET AND VARIABLE RATES, FOR THE MANAGEMENT OF DIABETES MELLITUS IN PERSONS REQUIRING INSULIN. THE PARADIGM REAL-TIME REVEL SYSTEM CONSISTS OF THE PARADIGM MMT-523/MMT-723 INSULIN PUMPS, THE ENLITE GLUCOSE SENSOR (MMT-7008), AND THE MINILINK TRANSMITTER (MMT-7703). USE OF THE PARADIGM MMT-523/MMT-723 INSULIN PUMPS WITH THE OPTIONAL SENSOR AND TRANSMITTER COMPONENTS IS INDICATED FOR CONTINUOUS OR PERIODIC MONITORING OF GLUCOSE LEVELS IN THE FLUID UNDER THE SKIN, AND POSSIBLE LOW AND HIGH BLOOD GLUCOSE EPISODES IN ADULTS (AGES 18 AND OLDER). ENLITE SENSOR: THE ENLITE SENSOR (MMT-7008) IS INTENDED FOR USE WITH THE PARADIGM REAL-TIME REVEL INSULIN PUMP SYSTEMS (MMT-523/MMT-723) TO CONTINUOUSLY MONITOR GLUCOSE LEVELS IN PERSONS WITH DIABETES.GLUCOSE VALUES PROVIDED BY THE PARADIGM REAL-TIME REVEL SYSTEM ARE NOT INTENDED TO BE USED DIRECTLY FOR MAKING THERAPY ADJUSTMENTS, BUT RATHER TO PROVIDE AN INDICATION OF WHEN A FINGERSTICK MAY BE REQUIRED. ALL THERAPY ADJUSTMENTS SHOULD BE BASED ON MEASUREMENTS OBTAINED USING A HOME GLUCOSE MONITOR AND NOT ON THE SENSOR GLUCOSE READINGS PROVIDED BY THE PARADIGM REAL-TIME REVEL SYSTEM.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MDS. The earliest in FDA's data is P980022, decided Jun 15, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Medtronic Minimed
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261962 · Decided Jul 9, 2026 · 28 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- MiniMed Flex pump510(k)
K253743 · Decided Mar 12, 2026 · 108 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
K253701 · Decided Feb 3, 2026 · 71 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.